Étude ARCS-Multi : étude de phase 1b évaluant l’efficacité et la sécurité de l’anétumab ravtansine associé au cisplatine chez des patients ayant un cholangiocarcinome, associé à la gemcitabine chez des patients ayant un adénocarcinome du pancréas ou en monothérapie chez des patients ayant d’autres tumeurs solides, exprimant la mésothéline, métastatiques ou non métastatiques à un stade avancé. Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cancers humains. On distingue 2 ...

• Country France
• organs Pancréas, Voies biliaires, Tumeurs solides
• Specialty Chimiothérapie, Immunothérapie - Vaccinothérapie

Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas To determine the number of infective episodes in patients with high grade gliomas during treatment with 10% intravenous immunoglobulin (Kiovig) compared with placebo (normal saline).

• Country None
• organs None
• Specialty None

Estudio de fase II, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de sorafenib comparado con placebo en pacientes con cáncer epitelial de ovario o con cáncer peritoneal primario que han alcanzado una respuesta clínica completa después de quimioterapia estándar con platino/taxano. (A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy) The objective of this study is to evaluate the efficacy and safety of sorafenib compared to placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer patients who have achieved a complete clin...

• Country None
• organs None
• Specialty None

Efficacy and safety of two different aflibercept regimens in subjects with nAMD To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with nAMD.

• Country None
• organs None
• Specialty None

Treating neovascular age-related Macular degeneration with Aflibercept Background and study aims Age-related macular degeneration (AMD) is the most common cause of vision loss in people over 50. It involves the gradual damage to a part of the eye called the macula. The m...

• Country None
• organs None
• Specialty None

The ACROSS-China trial Not provided at time of registration

• Country None
• organs None
• Specialty None

A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing 16 mg Candesartan Cilexetil Estudio para probar la efectividad de un comprimido que contiene tanto Nifedipino como Candesartán Cilexetilo, en adultos con presión arterial alta y cuya presión arterial no está bien controlada con comprimidos que contienen Candesartán Cilexetilo 16 mg The primary objective is to demonstrate the efficacy of two FDCs of nifedipine GITS and candesartan cilexetil compared to candesartan cilexetil monotherapy in subjects not adequately controlled on can...

• Country None
• organs None
• Specialty None

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o.

• Country None
• organs None
• Specialty None

Assess safety and efficacy of BAY 1002670 in subjects with uterine fibroids Evaluar la eficacia y la seguridad de BAY 1002670 en pacientes con miomas uterinos To assess the dose-response relationship of BAY 1002670 in subjects with uterine fibroids. Evaluar la relación dosis-respuesta de BAY 1002670 en pacientes con miomas uterinos.

• Country None
• organs None
• Specialty None

A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) Overall Survival

• Country None
• organs None
• Specialty None